THRD: Third Harmonic Bio Growth-Adjusted Market Cap to Net Income
The stable management of Third Harmonic Bio (THRD) maintains a strict financial policy while expanding its immunological portfolio. Tracking the PEG ratio demonstrates the current business valuation, where the 0.00 metric determines the parameter status. Successes of the THB001 drug in treating skin pathologies create positive momentum, while the recruitment of leading immunologists ensures a qualitative breakthrough in allergy treatment thanks to a unique scientific foundation.
Metric breakdowns and analytics for Third Harmonic Bio (THRD)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Third Harmonic Bio|THRD - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio thirdharmonicbio.com|THRD - Company Aggregate Debts|Debts to Book Value Third Harmonic Bio, Inc|THRD - Company Long-Term Liabilities|Amount of Current Liabilities Third Harmonic Bio|Intermediate Coverage Ratio thirdharmonicbio.com
- business earnings and investment ratios data:
THRD - Net Profit|Company Profit Forecast Third Harmonic Bio|THRD - Price to Earnings Ratio|Future Price to Earnings Multiple Third Harmonic Bio Inc|THRD - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Third Harmonic Bio, Inc|THRD - Operating profit before deduction of amortization|Earnings per share for the trailing year Third Harmonic Bio|THRD - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months thirdharmonicbio.com|THRD - Earnings growth in current year|Earnings growth forecast for next year Third Harmonic Bio
General company analysis:THRD - Third Harmonic Bio Inc.
The fabless model of Third Harmonic Bio (THRD), which delegates molecule synthesis to certified CMO plants, optimizes costs and mitigates the risks of production downtime. These operational advantages translate into the PEG ratio, which correlates the P/E ratio with earnings growth rates to determine whether the current price is undervalued relative to business dynamics; a value below one signals a fundamental undervaluation of the asset.
Who Third Harmonic Bio competes with
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|DNTH: Price/Earnings to Growth Multiple|Pharvaris Pharma - Company Value to Earnings Growth Ratio|ABCL: PEG Multiple|tourmalinebio.com - Growth-Adjusted Payback Ratio|PGEN (Precigen) - PEG Multiple|Pharming Group NV (PHAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Nektar (NKTR)|UPB (Upstream Pharma) - Growth-Adjusted Payback Ratio|PEG Multiple ZBIO (Zenas Biopharma Inc)|IMNM: Growth-Adjusted P/E Ratio|GOSS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio KALV (KalVista Pharma)|SEPN: PEG Multiple|Pieris Corp - Growth-Adjusted Payback Ratio|SVRA (Savara Inc.) - PEG Multiple|PEG Multiple rigel.com|Price/Earnings to Growth Ratio AnaptysBio (ANAB)|ATXS (Astria Therapeutics Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio enGene Bio ENGN|RAPT - Price/Earnings to Growth Multiple|JBIO - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate aclaristx.com|Kyverna Therapeutics, Inc. (KYTX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TLSA|CABA (Cabaletta Bio, Inc) - PEG Multiple|Ventyx Biosciences, Inc (VTYX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple THTX|Price/Earnings to Growth Multiple avalotx.com AVTX|Eledon Pharmaceuticals, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AGEN|Climb Bio, Inc. - PEG Multiple|ZURA: Price/Earnings to Growth Ratio|ATYR: PEG Multiple|ADAG - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio ImageneBio|Price to Earnings Adjusted for Growth Rate Shattuck Therapeutics STTK|Price/Earnings to Growth Multiple EQ (Equillium, Inc.)|Company Value to Earnings Growth Ratio CNTB|PEG Multiple IMUX (Immunic)|Growth-Adjusted Payback Ratio ATRA|IFRX - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio XFOR (X4 Pharmaceuticals Inc.)|ACET: PEG Multiple|Growth-Adjusted P/E Ratio CELU|Price/Earnings to Growth Ratio INmune Bio, Inc.|barinthusbio.com - Market Cap to Earnings and Growth Ratio|PEG Multiple KZR|SABS (SAB Biotherapeutics Inc.) - Growth-Adjusted Payback Ratio|PEG Multiple AKTX (Akari Therapeutics plc)|PEG Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio GOVX (geovax.com)|Edesa Biotech (EDSA) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple iBio Inc|CARM (Carisma Therapeutics Inc) - PEG Multiple|PEG Multiple XTL Bio|Price/Earnings to Growth Multiple BOLT (Bolt Biotherapeutics)|HCWB (hcwbiologics.com) - Growth-Adjusted Payback Ratio|PEG Multiple APVO (Aptevo Therapeutics Inc.)|Growth-Adjusted Market Cap to Net Income aimimmuno.com (AIM)|ADTX - Price/Earnings to Growth Ratio|GRI Bio Corporation (GRI) - Price/Earnings to Growth Multiple|XORTX Therapeutics Inc. (XRTX) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple reshapelifesciences.com|Price/Earnings to Growth Multiple REVB|PEG Multiple Indaptus Therapeutics Inc|Price/Earnings to Growth Ratio Scinai (SCNI)|calcimedica.com - Growth-Adjusted P/E Ratio|PEG Multiple AFMD (Affimed N.V.)|Allakos Inc (ALLK) - Price to Earnings Adjusted for Growth Rate|HOOK: Price/Earnings to Growth Multiple|IGM Biosciences, Inc. - Company Value to Earnings Growth Ratio|ITOS: PEG Multiple|Ocean Biomedical Corp - Growth-Adjusted Payback Ratio|TCBP (TC Biopharm) - PEG Multiple
